Skin Affecting Patents (Class 514/18.6)
-
Publication number: 20120251613Abstract: A method of stimulating melanogenesis in a skin surface of a patient, by treating the skin surface with a topical formulation comprising an effective amount of 17-phenyl-18,19,20-trinor-PGF2? ethyl amide in a dermatologically acceptable carrier. The topical formulation may be a cream, a gel, a lotion, a spray, an ointment, an aqueous solution, a nonaqueous solution, or a transdermal patch. The dermatologically acceptable carrier may contain an oily carrier or an aqueous carrier.Type: ApplicationFiled: July 29, 2011Publication date: October 4, 2012Applicant: AGILA SPECIALITIES PVT. LTD.Inventors: Rajeev JAIN, Tarun Narang, Satya Srinivas Chetlapalli
-
Publication number: 20120245086Abstract: The present invention relates to a WNT10-derived peptide, a composition for improving hair loss and skin conditions using the same, and a composition for treating a WNT10 signal transduction pathway-related disorder and DKK-1 protein-induced disorder using the same. WNT10-derived peptide of the present invention possesses identical or similar activities to natural-occurring WNT10, and has much higher stability and skin penetration potency than natural-occurring WNT10. Therefore, the composition containing the present peptide not only shows excellent effects on improvement in hair loss (for example, promotion of hair growth or production of hair), but also has superior efficacies on treatment of a WNT10 signal transduction pathway-related disorder and a DKK-1 protein-induced disorder. In addition, the outstanding activity and stability of the present peptide described above may be greatly advantageous in application to pharmaceutical compositions, quasi-drugs and cosmetics.Type: ApplicationFiled: November 24, 2009Publication date: September 27, 2012Applicant: CAREGEN CO., LTD.Inventors: Young Ji Chung, Eun Mi Kim, Sang Su Song, Kyoung Mi Cho
-
Publication number: 20120245097Abstract: Disclosed herein is a synthetic peptide, which has an amino acid sequence that has 20-39 amino acid residues. The synthetic peptide has at least 80% amino acid sequence identity to SEQ ID NO: 1, and includes at least 20 consecutive residues that has at least 90% amino acid sequence identity to residues 11-30 of SEQ ID NO: 1. Also disclosed herein are compositions containing the synthetic peptide and applications thereof. According to various embodiments of the present disclosure, the synthetic peptide is useful in promoting stem cells proliferation or wound healing.Type: ApplicationFiled: March 23, 2012Publication date: September 27, 2012Inventors: Yeou-Ping Tsao, Tsung-Chuan Ho
-
Publication number: 20120245079Abstract: Provided are high affinity T cell receptor variable regions that are useful for treating diseases caused by superantigens including atopic dermatitis, pneumonia and delayed wound healing. The variable regions contain mutants that result in high affinity binding to the superantigen.Type: ApplicationFiled: September 3, 2010Publication date: September 27, 2012Inventors: David M. Kranz, Patrick Schlievert
-
Patent number: 8273712Abstract: A method of promoting healing of a wound in a patient, the method comprising administering to the patient (i) a prostaglandin E (PGE) or an agonist thereof and/or an agent that increases the local concentration or effect of PGE and (ii) granulocyte-macrophage colony stimulating factor (GMCSF) or a derivative thereof. Use of (i) a PGE or an agonist thereof and/or an agent that increases the local concentration or effect of PGE and (ii) GMCSF or a derivative thereof in the preparation of a medicament for promoting healing of a wound in a patient. A wound dressing, bandage or fibrin glue comprising (i) a PGE or an agonist thereof and/or an agent that increases the local concentration or effect of PGE and (ii) GMCSF or a derivative thereof.Type: GrantFiled: November 24, 2006Date of Patent: September 25, 2012Assignee: Medical Research CouncilInventor: Rodney Kelly
-
Publication number: 20120238500Abstract: The present application is directed to the discovery that preparations of hedgehog polypeptides can be used to control the formation and/or maintenance of epithelial tissue.Type: ApplicationFiled: December 19, 2011Publication date: September 20, 2012Applicant: Curis, Inc.Inventor: Elizabeth A. Wang
-
Publication number: 20120238506Abstract: The invention relates to a composition containing an extract of seeds of Acacia macrostachya. Advantageously the composition is cosmetic, pharmaceutical, dermatological or nutraceutical. The invention also relates to a method for extracting a Acacia macrostachya seed extract, as well as to the resulting extract. The invention further relates to one such composition or one such extract for use in the prevention or treatment of disorders and diseases affecting the skin, mucosae or appendages, for use in the prevention or treatment of vascular disorders and for use in the prevention or treatment of adipose tissue alterations. Moreover, the invention relates to a method for cosmetic care of the Skin, appendages and mucosae in order to improve the condition or appearance thereof, comprising the administration of one such composition or one such extract.Type: ApplicationFiled: November 30, 2010Publication date: September 20, 2012Inventors: Philippe Msika, Alex Saunois, Sophie Leclere-Bienfait, Caroline Baudoin
-
Publication number: 20120237624Abstract: The invention relates to a composition comprising a Vigna unguiculata seed extract. The composition is advantageously cosmetic, pharmaceutical, dermatological or nutraceutical. The invention further relates to a method for extracting a Vigna unguiculata seed extract, as well as to the resulting extract. The invention further relates to one such composition or one such extract for use in the prevention or treatment of disorders or pathologies of the skin, mucosae or appendages, for use in the prevention or treatment of vascular disorders, or for use in the prevention or treatment of adipose tissue alterations. Finally, the invention relates to a method for cosmetic care of the skin, appendages or mucosae, in order to improve the condition or appearance thereof, comprising the administration of one such composition or one such extract.Type: ApplicationFiled: November 30, 2010Publication date: September 20, 2012Inventors: Philippe Msika, Alex Saunois, Sophie Leclere-Bienfait, Caroline Baudoin
-
Publication number: 20120238503Abstract: The present invention relates to human laminin ?2 chain LG3 domain and active peptides promoting cell adhesion, spreading, migration, and neurite outgrowth. More particularly, it was found that when nerve cells are incubated using human laminin ?2 chain LG3 domain and active peptides in the LG3 domain, cell adhesion, spreading, migration, and neurite outgrowth of nerve cells promote and the promotion of cell adhesion, spreading, migration, and neurite outgrowth of nerve cells are integrin-mediated and achieved by the activation of PKC? and FAK phosphorylation. Thus, the present invention can be very useful for researches on cell adhesion, spreading, migration, and neurite outgrowth activities of cells which are focused on nerve cells and mediated by various extracellular matrix proteins including laminin, manufacture of artificial nerve conduits, burns treatment, wounds treatment, and tissue regeneration.Type: ApplicationFiled: March 12, 2012Publication date: September 20, 2012Applicant: SNU R&DB FOUNDATIONInventor: Byung-Moo MIN
-
Publication number: 20120238505Abstract: The present invention relates to the use of a peptide, or derivative thereof of general formula X1-X2-X3-ThT-X4-LyS-X5-ATg-X6 for promoting accelerated wound healing with reduced scarring. X1 is Ala or Gly; X2 is Tyr or Phe; X3, X4 and X5 are independently selected from the group comprising Met, He, Leu and Val; and X6 is selected from the group comprising Asp, Gln and Glu.Type: ApplicationFiled: October 7, 2011Publication date: September 20, 2012Applicant: RENOVO LIMITEDInventors: Mark W.J. Ferguson, Nick Occleston, Amanda Deakin, Sharon O'Kane
-
Patent number: 8268785Abstract: The invention relates to the use of PDE5 inhibitors, preferably sildenafil or tadalafil, optionally in combination with a further active ingredient, for treating and/or preventing hypopigmentary disorders.Type: GrantFiled: July 15, 2005Date of Patent: September 18, 2012Assignee: Switch Biotech AGInventor: Heidemarie Peuker
-
Publication number: 20120231994Abstract: The present invention is directed to modulators of eosinophilic and neutrophilic function and the use of such modulators for treatment of eosinophil-associated and neutrophil-associated diseases.Type: ApplicationFiled: June 2, 2010Publication date: September 13, 2012Applicant: NIKAN PHARMACEUTICALS, LLCInventor: John D. Benson
-
Patent number: 8263046Abstract: Used as cooling agents are the compounds of formula (I), wherein Y is carbonyl (C(?O)) or sulfonyl (SO2—); and X is OCH3, CN, C(?O)NHR, C(?O)OR, or halogen; and R is hydrogen or C1-C4 alkyl.Type: GrantFiled: October 23, 2006Date of Patent: September 11, 2012Assignee: Givaudan S.A.Inventors: Christophe C. Galopin, Lori W. Tigani, Jay Patrick Slack, Pablo Victor Krawec, Lucienne Cole
-
Patent number: 8263118Abstract: The present invention describes a new bioresorbable filler constituted by hyaluronic acid and/or the derivatives thereof structured with/in phospholipid liposomes, which increase the residence time of the starting polymer in situ. Said fillers described herein are substantially intended to increase the soft tissues in aesthetic surgery and dermocosmetics for the correction of mild to medium defects, but because of their special characteristics they can also be used in other fields of application.Type: GrantFiled: February 15, 2012Date of Patent: September 11, 2012Assignee: Fidia Farmaceutici S.p.A.Inventors: Lanfranco Callegaro, Devis Galesso, Anna Taglienti
-
Publication number: 20120225107Abstract: Provided are dermatological compositions for skin and scar treatment, methods of making the compositions and methods of applying the compositions, which result in improved skin and scar whitening performance. In one form, the dermatological composition for skin and scar treatment includes 33 to 60 wt. % of one or more hydrophilic benefiting ingredients, and 40 to 60 wt. % of an anhydrous hydrophilic/amphiphatic base comprising 1 to 35 wt. % of propylene glycol, 1 to 15 wt. % of polyethylene glycol, 1 to 20 wt. % of cetyl alcohol, 1 to 20 wt. % stearyl alcohol, 1 to 10 wt. % of ethoxydiglycol, 0.1 to 2.0 wt. % of dexapanthenol, 0.1 to 1.0 wt. % of phenoxyethanol, and 0.1 to 2.0 wt. % of tocophersolan (TPGS). The one or more hydrophilic benefiting ingredients may include skin whitening agents, antioxidants, extracts, antifungal/antibacterial/anti-acne agents, polypeptides, anti-inflammatory agents, keratolytic agents, amino acids and combinations thereof.Type: ApplicationFiled: March 2, 2012Publication date: September 6, 2012Inventor: Caridad HECHAVARRIA
-
Publication number: 20120219536Abstract: Methods of treating a wound, an ulcer and/or a burn responsive to inhibition of xanthine oxidoreductase to thereby reduce uric acid in an animal are provided wherein the methods include topical administration of a therapeutic agent effective for treatment of the wound, the ulcer and/or the burn wherein the therapeutic agent inhibits xanthine oxidoreductase to thereby reduce uric acid in the wound, ulcer and/or burn. Also provided are methods and kits for determining the severity of a wound, a burn and/or an ulcer including the step of detecting one or more of (i) a level of uric acid; (ii) a level of one or more uric acid precursors; and (iii) a presence, or absence of or level of xanthine oxidoreductase.Type: ApplicationFiled: August 13, 2010Publication date: August 30, 2012Applicant: Queensland University of TechnologyInventors: Melissa Laura Fernandez, Gary Keith Shooter
-
Publication number: 20120219574Abstract: The present invention provides for the identification of an antigen surrogate to the native antigens for the autoimmune disease pemphigus vulgaris. Ligands are discovered using large random peptoid or cyclic peptoid libraries that are screened against known antibodies to autoimmune diseases. The ligands may be useful as drugs in the treatment of such diseases and can also be used in combination with the concomitant removal of T-cells associated with autoimmune disorders.Type: ApplicationFiled: April 10, 2012Publication date: August 30, 2012Applicant: OPKO Pharmaceuticals, LLCInventors: Phillip FROST, Thomas Kodadek
-
Publication number: 20120219544Abstract: The adhesive composition for soft tissues, the adhesive composition for wound dressing or the wound dressing agent composition of the present invention is an adhesive composition for soft tissues, an adhesive composition for wound dressing or a wound dressing agent composition, comprising a monomer (A), a polymer (B) and a polymerization initiator composition (C) containing an organoboron compound, and is characterized by having a viscosity of 0.4 to 75,000 cp within 30 seconds after mixing of the components (A), (B) and (C). The composition of the present invention not only has low toxicity, low harmfulness and high adhesive strength but also is excellent in workability during application and is capable of forming films of excellent properties.Type: ApplicationFiled: November 18, 2010Publication date: August 30, 2012Applicant: MITSUI CHEMICALS, INC.Inventors: Noriaki Asada, Shinya Aoki, Hiroshi Naruse, Shoichi Miyakoshi, Masami Arata
-
Publication number: 20120220536Abstract: C-terminal endostatin polypeptides are disclosed herein. In some embodiments, these polypeptides include or consist of (1) at least at least 40 consecutive amino acids of the amino acid sequence set forth as amino acids 133-180 of SEQ ID NO: 2, SEQ ID NO: 13 or SEQ ID NO: 4; (2) at least 40 consecutive amino acids of the amino acid sequence set forth as amino acids 133-180 of SEQ ID NO: 2, SEQ ID NO: 13 or SEQ ID NO: 4 with at most 5 amino acid substitutions, (3) the amino acid sequence set forth as amino acids 133-180 of SEQ ID NO: 2, SEQ ID NO: 13 or SEQ ID NO: 4; or (4) the amino acid sequence set forth as amino acids 133-180 of SEQ ID NO: 2, SEQ ID NO: 13 or SEQ ID NO: 4 with at most 5 amino acid substitutions; wherein the polypeptide has anti-fibrotic activity and wherein the polypeptide does not comprise amino acids 1-92 of SEQ ID NO: 2, SEQ ID NO: 13 or SEQ ID NO: 4.Type: ApplicationFiled: October 22, 2010Publication date: August 30, 2012Inventors: Carol A. Feghali-Bostwick, Yukie Yamaguchi
-
Publication number: 20120213843Abstract: A lipid layer forming wound healing promoting composition comprising volatile silicone oil, polar lipid, C2-C4 aliphatic alcohol, and a wound healing agent, in particular a low to medium size natural or synthetic peptide. Also disclosed is a method of forming the lipid layer on a wound and a medical patch provided with the composition.Type: ApplicationFiled: November 3, 2010Publication date: August 23, 2012Applicant: Lipidor ABInventors: Anders Carlsson, Jan Holmback
-
Publication number: 20120214743Abstract: The present invention provides an itch suppressant containing cholecystokinin 2 receptor agonist such as a peptide having an amino acid sequence homologous with a partial amino acid sequence of at least seven C-terminal amino acids of the peptide having the amino acid sequence represented by SEQ:ID No. 1 as an active ingredient as a rapid-acting itch suppressant effective in treating skin illnesses associated with strong itch such as atopic dermatitis having few side effects. [SEQ:?ID?No.Type: ApplicationFiled: October 22, 2010Publication date: August 23, 2012Applicant: University of Occupational and Environmental Health, JapanInventors: Yoshiki Tokura, Shoko Fukamachi
-
Publication number: 20120214731Abstract: The present invention relates to a new compound useful as a modulator of melanocortin receptors. In particular, the present invention relates to a compound WS727713, a process for production of the compound by culturing, in a culture medium, a WS727713-producing strain belonging to Pseudonocardia and recovering the compound from a culture broth, a pharmaceutical composition containing the compound, and uses of the compound.Type: ApplicationFiled: January 19, 2012Publication date: August 23, 2012Inventors: Takanao Otsuka, Hirotsugu Ueda, Keiko Fujie, Hideyuki Muramatsu, Michizane Hashimoto, Shigehiro Takase
-
Publication number: 20120207812Abstract: There is disclosed a skincare composition suitable for topical application to the skin. The composition comprises salicylic acid or a salt thereof and hydrolysed milk protein. The composition is useful in the treatment of acne.Type: ApplicationFiled: April 23, 2012Publication date: August 16, 2012Applicant: RECKITT & COLMAN (OVERSEAS) LIMITEDInventors: Iris STRODTHOLZ, Timm SCHMIDT, Ivana STRAHINJIC
-
Patent number: 8242076Abstract: A novel laminin polypeptide comprising the amino acid sequence set forth by SEQ ID NO:3 is disclosed. Also disclosed are compositions-of-matter comprising a polysaccharide (e.g., hyaluronic acid) and the novel laminin polypeptide; or hyaluronic acid, a laminin polypeptide and an antioxidant (e.g., superoxide dismutase), as well as matrices and hydrogels comprising same which can be used for ex vivo or in vivo tissue formation and for treatment of pathologies characterized by diseased, damaged or loss of tissue.Type: GrantFiled: August 13, 2008Date of Patent: August 14, 2012Assignees: Ramot at Tel-Aviv University Ltd., The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical CenterInventors: Shimon Rochkind, Zvi Nevo
-
Publication number: 20120202733Abstract: Peptides are provided consisting of L- and/or D-amino acids and combinations thereof, which affect myeloid cells by action on the triggering receptors expressed on myeloid cells (TREMs), including TREM-1 and TREM-2. The peptides act on the TREM/DAP-12 signaling complex. Also provided are lipid and sugar conjugated peptides comprising L- or D-amino acids. A method is provided of designing the peptides and lipid- and/or sugar-conjugated peptides comprising L- or D-amino acids. The disclosure relates to the therapy of various myeloid cell-related disease states involving the use of these peptides and compounds. The peptides and compounds are useful in the treatment and/or prevention of a disease or condition where myeloid cells are involved or recruited. The peptides of the present invention also are useful in the production of medical devices comprising peptide matrices (for example, medical implants and implantable devices).Type: ApplicationFiled: October 13, 2010Publication date: August 9, 2012Applicant: SIGNABLOK, INC.Inventor: Alexander B. Sigalov
-
Publication number: 20120196790Abstract: The present application relates to cyclic depsipeptides, or derivatives thereof, having the structure of formula (I), and uses thereof, e.g. as inhibitors of kallikrein 7 and human neutrophil elastase.Type: ApplicationFiled: February 14, 2012Publication date: August 2, 2012Applicant: NOVARTIS AGInventors: Philipp KRASTEL, Brigitta-Maria LIECHTY, Josef Gottfried MEINGASSNER, Esther SCHMITT, Erwin Paul SCHREINER
-
Publication number: 20120196789Abstract: The present invention provides peptide-based peroxidase inhibitors having the formula AA1-AA2-AA3, wherein AA1 is a positively charged, negatively charged or neutral amino acid, AA2 is a redox active amino acid, and AA3 is an amino acid possessing a reducing potential such that AA3 is capable of undergoing a redox reaction with a radical of amino acid AA2 or a retro or retro-inverso analog thereof. The result of such a combination is a highly effective inhibitor of peroxidase activity that has potent anti-inflammatory properties in widely diverse models of vascular disease and injury. Exemplary tripeptides effectively inhibit peroxidase mediated LDL oxidation, increase vasodilation in SCD mice, inhibit eosinophil infiltration and collagen deposition in asthma mice, inhibit acute lung injury, and decrease ischemic injury of the heart.Type: ApplicationFiled: October 5, 2010Publication date: August 2, 2012Inventors: Hao Zhang, Yang Shi, Hao Xu, Kirkwood A. Pritchard, JR.
-
Patent number: 8231916Abstract: The present invention concerns the use of a rice protein hydrolysate in order to pigment the skin and skin appendages. Thus, it is possible to intensify the normal pigmentation of the skin without sunlight. Preferred areas of applications are repigmentation of white patches of the skin, repigmentation of white patches of the skin as a consequence of pityriasis or due to the use of dermocorticoids; acceleration and intensification of the tanning process, stimulation of the constitutive photoprotection and improvement of the phototype, prevention of skin photocarcinogenesis. Advantageously, the rice protein hydrolysate comprises peptides of which at least 50% have a molecular mass in the range of between 300 and 3,500 Da.Type: GrantFiled: July 18, 2007Date of Patent: July 31, 2012Assignee: Laboratoires ExpanscienceInventors: Philippe Msika, Dalale Naaïmi
-
Publication number: 20120183538Abstract: The invention provides SPARC antisense oligonucleotides and methods of their use in proliferative diseases such as cancer and hepatic fibrosis.Type: ApplicationFiled: July 9, 2010Publication date: July 19, 2012Applicant: ABRAXIS BIOSCIENCE, LLCInventors: Vuong Trieu, Larn Hwang, Neil Desai
-
Publication number: 20120184493Abstract: Described herein are topical formulations for use in the treatment or prevention of dermatological diseases, disorders, or conditions in a mammal.Type: ApplicationFiled: July 28, 2010Publication date: July 19, 2012Applicant: PANMIRA PHARMACEEUTICALS, LLCInventor: John Howard Hutchinson
-
Publication number: 20120183541Abstract: The present invention relates to a method of promoting hair growth comprising administering a fibroblast growth factor receptor 4 (FGFR4) extracellular domain (ECD), including native FGFR4 ECDs, variants, fragments, and fusion molecules, to a subject in an amount sufficient to promote hair growth.Type: ApplicationFiled: September 15, 2010Publication date: July 19, 2012Inventors: Thomas Brennan, Robert Dean, W. Michael Kavanaugh, Janine Powers
-
Publication number: 20120178697Abstract: The Wnt signaling pathways are involved in embryo development as well as in tumorigenesis. Dishevelled (Dvl) tranduces Wnt signals from the receptor Frizzled (Fz) to downstream components in canonical and non-canonical Wnt signaling pathways, and the Dvl PDZ domain plays an essential role in both pathways, and the Dvl PDZ domain binds directly to Fz receptors. In the present invention using NMR-assisted virtual ligand screening, several compounds were identified and were found to bind to the Dvl PDZ domain. Molecular dynamics simulation was used to analyze the binding between the PDZ domain and these compounds in detail. These compounds provide a basis for rational design of high-affinity inhibitors of the PDZ domain, which can block Wnt signaling by interrupting the Fz-Dvl interaction.Type: ApplicationFiled: April 1, 2005Publication date: July 12, 2012Inventors: Jie Zheng, Jufang Shan, Dianqing Wu
-
Patent number: 8217008Abstract: A soluble receptor to IL-20 having two polypeptide subunits, IL-20RA (formerly called ZcytoR7) and IL-20RB (formerly called DIRS1). The two subunits are preferably linked together. In one embodiment one subunit is fused to the constant region of the light chain of an immunoglobulin, and the other subunit is fused to the constant region of the heavy chain of the immunoglobulin. The light chain and the heavy chain are connected via a disulfide bond.Type: GrantFiled: October 7, 2010Date of Patent: July 10, 2012Assignee: ZymoGenetics, Inc.Inventors: Donald C. Foster, Wenfeng Xu, Karen L. Madden, James D. Kelly, Cindy A. Sprecher, Cameron S. Brandt, Mark W. Rixon, Scott R. Presnell, Brian A. Fox
-
Publication number: 20120172309Abstract: The present invention relates to a peptide of general formula (I): R1-(AA)n-X1-X2-Arg-Arg-Gly-X3-X4-(AA)p-R2. The present invention also relates to a cosmetic or pharmaceutical composition, containing at least one peptide of general formula (I), in a physiologically suitable medium. The present invention also relates to the use of a composition containing the peptide of general formula (I) as an active ingredient which activates human transglutaminase to reinforce the skin barrier function and to stimulate epidermal regeneration and differentiation. The invention also relates to a cosmetic treatment method for preventing and/or for combatting external stresses and signs of skin ageing.Type: ApplicationFiled: August 31, 2010Publication date: July 5, 2012Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Publication number: 20120172287Abstract: A novel polypeptide which has an excellent angiogenesis-inducing activity and an excellent antibacterial activity, and a novel angiogenesis-inducing agent which contains the polypeptide as an effective ingredient or a novel agent for treating a wound(s) which contains the polypeptide as an effective ingredient are disclosed. The polypeptide of the present invention is a polypeptide whose amino acid sequence is shown in any one of SEQ ID NOs:1 to 6, 8 and 10. The angiogenesis-inducing agent which contains the polypeptide of the present invention as an effective ingredient is useful for the prevention, amelioration or treatment of a disease such as a burns, decubitus, wound, skin ulcer, leg ulcer, diabetic ulcer, occlusive arterial disease and arteriosclerosis obliteran.Type: ApplicationFiled: May 25, 2010Publication date: July 5, 2012Applicant: ANGES MG, Inc.Inventors: Takefumi Gemba, Hideki Tomioka, Nao Tamura, Ryoko Sata, Akito Maeda, Akiko Tenma, Toshihide Kanamori, Yoshimi Saito, Shintaro Komaba, Ryuichi Morishita
-
Publication number: 20120157387Abstract: Provided are compounds which are prodrugs of D-gamma-glutamyl-D-tryptophan, methods of making the compounds and methods for using the compounds.Type: ApplicationFiled: February 20, 2012Publication date: June 21, 2012Applicant: APOTEX TECHNOLOGIES INC.Inventors: Tim Fat TAM, Regis Leung-Toung, Yingsheng Wang, Yanqing Zhao, Tao Xin, Wanren Li, Jolanta Maria Wodzinska, Vrajlal S. Rabadia, Birenkumar Shah, Christopher John Feeney
-
Patent number: 8198244Abstract: The present disclosure is generally related to methods of inducing non-palmoplantar skin to develop a palmoplantar phenotype, for example, methods for increasing skin thickness, decreasing skin pigmentation, and/or decreasing hair growth. In particular, disclosed herein are methods of using topical administration of DKK1 to increase skin thickness, decrease skin pigmentation, or reduce hair growth. Also disclosed are topical DKK1 compositions for inducing non-palmoplantar skin to develop a palmoplantar phenotype.Type: GrantFiled: December 7, 2007Date of Patent: June 12, 2012Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Vincent Hearing, Yuji Yamaguchi, Thierry Passeron
-
Publication number: 20120141483Abstract: The present invention provides indane acetic acids and their derivatives and methods for the treatment and/or prevention of psoriasis and/or Alzheimer's diseases using the same.Type: ApplicationFiled: June 3, 2010Publication date: June 7, 2012Inventor: Mary Katherine Delmedico
-
Publication number: 20120142605Abstract: The invention includes methods for treating patients having psoriasis and methods for testing the efficacy of such treatments. The methods include treating the patients with a TNF inhibitor plus a topical preparation containing a glucocorticoid.Type: ApplicationFiled: May 5, 2010Publication date: June 7, 2012Applicant: Amgen Inc.Inventors: Michele M. Hooper, Elizabeth H.Z. Thompson
-
Publication number: 20120141538Abstract: The present invention concerns modulators of the CX3CR1 receptor. More specifically, antagonists and agonists of the CX3CR1 receptor have been identified. These antagonists and agonists can be used for treating an inflammatory disorder, an autoimmune disorder, a cardiovascular disease, a neurodegenerative disease, a graft versus host disease, a behavioral disorder, a cicatrisation disorder, a viral infection, cancer or pain. They may also be used as an adjuvant in a vaccine composition.Type: ApplicationFiled: December 16, 2009Publication date: June 7, 2012Applicant: UNIVERSITE PIERRE ET MARIE CURIE -PARIS VIInventors: Guy Gorochov, Karim Dorgham, Christophe Combadiere, Philippe Deterre
-
Publication number: 20120141416Abstract: The present invention relates to multimeric (e.g., dimeric, trimeric) forms of peptide vectors that are capable of crossing the blood-brain barrier (BBB) or efficiently entering particular cell types. These multimeric peptide vectors, when conjugated to agents (e.g., therapeutic agents) are capable of transporting the agents across the BBB or into particular cell types. These compounds are therefore particularly useful in the treatment of neurological diseases.Type: ApplicationFiled: June 30, 2010Publication date: June 7, 2012Applicant: Angiochem Inc.Inventors: Michel Demeule, Christian Che, Carine Thiot
-
Publication number: 20120142595Abstract: Provided herein are tissue protective peptides derived from or sharing consensus sequences with portions of cytokine receptor ligands, including Erythropoietin (EPO), that are generally located on or within the region of the cytokine receptor ligand that faces away from a receptor complex while the ligand is bound to the receptor. Also provide herein are fragments, chimeras, as well as peptides designed to mimic the spatial localization of key amino acid residues within the tissue protective receptor ligands, e.g., EPO; methods for treating or preventing a disease or disorder using tissue protective peptides; and methods for enhancing excitable tissue function using tissue protective peptides.Type: ApplicationFiled: October 20, 2011Publication date: June 7, 2012Applicant: Araim Pharmaceuticals, Inc.Inventors: Anthony Cerami, Michael Brines, Thomas Coleman
-
Publication number: 20120135916Abstract: Methods are disclosed for determining progression of a condition, onset of a condition, or efficacy of treatment of a condition characterized by an adipocyte imbalance in a patient. In addition, methods are disclosed of treating diabetes, abnormal adipocyte activity, and insulin resistance using monomeric, homodimeric, and heterodimeric forms of certain C-terminal fragments of adiponectin receptor. In addition, methods of treating abnormal adipocyte activity, treating metabolic syndrome, causing insulin secretion, increasing insulin levels, inhibiting insulin degradation enzyme, treating Alzheimer's disease, treating cardiovascular disease associated with adiponectin levels, inhibiting ADAM-17 enzyme, inhibiting a protease, treating a condition associated with TNF-alpha, and treating a condition associated with HER2-neu are disclosed. Compositions, dosage forms, and kits are also disclosed.Type: ApplicationFiled: April 13, 2010Publication date: May 31, 2012Applicant: Siemens Healthcare Diagnostics Inc.Inventors: Michael J. Pugia, Rui Ma
-
Publication number: 20120135937Abstract: The present invention concerns an injectable composition comprising a filler or a botulinum toxin and an adrenergic receptor agonist, and its use for diminishing, decreasing or avoiding skin reactions due to injection, specially redness, ecchymosis, bruising, bleeding, erythema, oedema, necrosis, ulceration, swelling and/or inflammation.Type: ApplicationFiled: May 28, 2010Publication date: May 31, 2012Applicants: Galderma Research & Development, SymateseInventors: Isabelle Bertholon, Florence Brunel, Benjamin Herbage, Christophe Villard, Sylviane Villard
-
Patent number: 8187881Abstract: The invention is directed to methods for the treatment of wounds. Such methods utilize novel compositions, including but not limited to amnion-derived multipotent cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine suspension or ACCS), cell lysates derived therefrom, cell products derived therefrom, each alone or in combination.Type: GrantFiled: December 1, 2009Date of Patent: May 29, 2012Assignee: Stemnion, Inc.Inventors: Charlotte A. Smith, Catherine J. Trumpower, Vivienne S. Marshall
-
Patent number: 8188049Abstract: The present invention relates to peptides comprising the amino acid sequence represented by the following formula 1 and having the activities of epidermal growth factor and their uses: Cys-Met-Tyr-Ile-Glu-Linker-Arg-Gly-Asp (1) The EGF-mimicking peptides of the present invention possess identical functions or activities to natural-occurring human EGF and are able to promote the generation of autocrine EGF in cells. In addition the peptides of the present invention are much higher stability and skin penetration potency than natural-occurring EGF. Therefore, the composition containing the peptide exhibits excellent treatment and prevention efficacies on diseases or conditions demanding EGF activities, and can be advantageously applied to pharmaceutical compositions, quasi-drugs and cosmetics.Type: GrantFiled: October 8, 2007Date of Patent: May 29, 2012Assignee: Caregen Co., Ltd.Inventors: Yong-Ji Chung, Young Deug Kim, Eun Mi Kim, Jun Young Choi, Sang Su Song
-
Patent number: 8188050Abstract: The present invention concerns the use of peptide fragments of the protein SLC24A5 as active agents designed to induce, increase, or restore the synthesis of melanin in the melanocytes of the epidermis or of the pilar bulb, alone or in association with at least one other active agent, in a cosmetic composition or for the preparation of a pharmaceutical or particularly dermatological composition. The invention is also related to any composition containing the active agents.Type: GrantFiled: October 26, 2007Date of Patent: May 29, 2012Assignee: ISP Investments Inc.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Publication number: 20120129776Abstract: Disclosed are peptide ligands for G-protein coupled receptors that are useful for treating disorders associated with G-protein coupled receptor activation.Type: ApplicationFiled: September 18, 2007Publication date: May 24, 2012Inventors: Yossi Cohen, Ronen Shemesh, Amir Toporik, Zurit Levine, Assaf Wool, Dvir Dahary, Iris Hecht, Merav Beiman, Galit Rotman, Michal Ayalon-Soffer
-
Publication number: 20120129785Abstract: The invention encompasses a nutrition system for a companion animal that includes a plurality of pet food packets, wherein an amount of pet food corresponding to a single meal for a companion animal may be selected and wherein the amount of pet food is formulated to alleviate or manage a disorder in a companion animal. In various embodiments, the pet food packets include the nutritional requirements for a companion animal (e.g., protein, fiber, fat) as well as one or more ingredients that alleviate or manage a disorder in a companion animal.Type: ApplicationFiled: July 21, 2010Publication date: May 24, 2012Applicant: Hill's Pet Nutrition, Inc.Inventors: Leslie Fleuranges, Geoffrey Tolsdorf
-
Publication number: 20120129784Abstract: Oligopeptides according to formula (I) and/or (II), R1-Tyr-Pro-Trp-Phe-NH2 (I, SEQ ID NO:1); R1-Tyr-Pro-PhePhe-NH2 (II, SEQ ID NO:2), wherein R1 is linked to the NH2-group of the amino-terminal part of Tyr and is selected from the group consisting of —H; a linear saturated or unsaturated or branched saturated or unsaturated acyl group having 1 to 24 carbon atoms, which may be functionalized by a —OH, —SH, —COOH or —CONH+ group; a sterol or a sphingolipid group which is linked to the amino terminal part of Tyr via a bifunctional linker are disclosed. Cosmetic compositions containing the oligopeptides are also disclosed.Type: ApplicationFiled: December 16, 2011Publication date: May 24, 2012Applicant: Cognis IP Management GmbHInventors: Véronique Gillon, Philippe Moussou, Jean-Luc Contet-Audonneau, Olga Freis